Key Players
Competitive Landscape
FMI data suggests that commercial competition in the oral solid dosage pharmaceutical formulation sector divides between multinational originator drugmakers scaling high-potent oncology and oral peptide tablets and global generic manufacturers competing on rotary compression efficiency. Originator sponsors invest in continuous direct compression, hot-melt extrusion, and spray-dried amorphous solid dispersions to commercialize poorly soluble BCS Class II and Class IV molecules. Generic producers consolidate volume through automated multi-shift tableting and vertically integrated active pharmaceutical ingredient supply.
From mid-2025 through October 2026, pharmaceutical manufacturers redirected capital toward selective oral oncology tablets and third-party high-containment CDMO services and extended-release CNS matrices and oral macrocyclic peptides. Novartis scaled Kisqali and Scemblix oral oncology output while Pfizer expanded Pfizer CentreOne contract manufacturing receipts by 17%, Teva grew Austedo XR tablets by 34%, and Merck advanced enlicitide decanoate.
Company developments mapped to drivers, trends and opportunities (2026 to 2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| October 2026: Novartis grew Q3 Kisqali (+37% cc) and Scemblix (+67% cc) oral oncology receipts [18]. | Targeted oral kinase inhibitors replace hospital intravenous chemotherapy. | Oncology pipelines shift toward selective allosteric and CDK4/6 film-coated tablets. | Companion cold-form blister packs with calendarized dosing improve outpatient oncology adherence. |
| February 2026: Pfizer reported 17% growth in Pfizer CentreOne CDMO receipts to USD 1,338 million [8]. | Biotech sponsors lack captive high-containment OEB 4/5 tableting suites. | Big pharma monetizes specialized solid-dosage capacity via third-party CDMO contracts. | High-potent oral oncology tech transfers generate recurring contract manufacturing margins. |
| January 2026: Teva grew once-daily Austedo XR / Austedo receipts by 34% to USD 2.26 billion [10]. | Multi-dose immediate-release CNS regimens suffer from peak-trough side effects. | Manufacturers reformulate movement-disorder drugs into once-daily extended-release osmotic or matrix tablets. | 505(b)(2) once-daily tablet lifecycle extensions defend brand valuation against generic entry. |
| July 2025: Merck announced positive Phase 3 CORALreef results for oral PCSK9 inhibitor enlicitide decanoate [7]. | Patients prefer daily oral lipid-lowering tablets over subcutaneous PCSK9 injections. | Permeation-enhanced macrocyclic peptides enable oral delivery of biologic-like targets. | Oral peptide tableting creates a multi-billion-dollar cardiometabolic growth vector. |
Source: Future Market Insights, Oral Solid Dosage Pharmaceutical Formulation Market Report, 2026 to 2036.
Pfizer Inc., Novartis AG, and AstraZeneca PLC lead high-potency oral oncology and continuous tableting across global hospital and retail formularies. Merck & Co., Inc. and Teva Pharmaceutical Industries Ltd. scale oral cardiometabolic peptides, extended-release CNS tablets, and high-volume generic solid dosage portfolios.
How are key market participants positioned in the oral solid dosage pharmaceutical formulation market?
Pfizer Inc., Novartis AG, and AstraZeneca PLC anchor premium oral solid value across targeted oncology kinase inhibitors and cardiovascular tablets while offering specialized contract manufacturing. Merck & Co., Inc. leads in oral macrocyclic peptide and cardiometabolic formulation, whereas Teva Pharmaceutical Industries Ltd. dominates global generic tableting and extended-release CNS matrices.
What qualification or purchasing requirements matter most to prospective buyers?
Health-system tenders and pharmacy buyers require verified United States and European Pharmacopoeia content and dissolution uniformity, ICH Zone IVb moisture stability in Alu-Alu blisters or desiccant bottles, and uninterrupted multi-site API and finished-dose supply.
Which product or application capabilities distinguish the leading companies?
Top manufacturers differentiate through continuous direct compression with inline PAT and low-temperature hot-melt extrusion and high-containment OEB 4/5 occupational exposure handling.
How does geographic reach differ among the key market players?
Every benchmarked manufacturer runs GMP-certified tableting plants spanning North America and Europe and Asia while scaling Latin American packaging hubs in Brazil and Mexico.
Representative Company Overview
| Company | Positioning | Verified Development |
|---|---|---|
| Pfizer Inc. | Global innovator and CDMO operator supplying oral oncology, cardiovascular, and anti-infective tablets. | Reported USD 62.6 billion in 2025 receipts and 17% growth in Pfizer CentreOne CDMO receipts to USD 1,338 million in February 2026 [8]. |
| Novartis AG | Pure-play innovative medicines leader scaling targeted oral oncology tablets Kisqali and Scemblix. | Reported USD 42.0 billion in 9M 2026 net receipts in October 2026 with Q3 Kisqali up 37% cc and Scemblix up 67% cc [18]. |
| AstraZeneca PLC | Biopharmaceutical innovator commercializing Tagrisso, Calquence, Lynparza, and Farxiga oral solid tablets. | Delivered 16 positive Phase 3 trials in February 2026 [11] and co-authored high-throughput HME ASD screening in August 2026 [19]. |
| Merck & Co., Inc. | Global pharmaceutical leader developing oral cardiometabolic peptides and oncology small molecules. | Reported positive Phase 3 CORALreef results for oral PCSK9 tablet enlicitide decanoate in July 2025 [7]. |
| Teva Pharmaceutical Industries Ltd. | Global generic oral solid leader and developer of once-daily Austedo XR extended-release tablets. | Reported 2025 receipts of USD 17.3 billion (+4%) in January 2026 with Austedo franchise up 34% to USD 2.26 billion [10]. |
Research Methodology
The oral solid dosage pharmaceutical formulation market assessment was conducted using a combination of primary research, secondary desk research, and top-down and bottom-up data triangulation for the 2026 to 2036 forecast period. Secondary research reviewed company annual reports and SEC Form 10-K filings and United States and European Pharmacopoeia monographs, IQ Consortium position papers, and peer-reviewed pharmaceutics journals. Primary research incorporated structured interviews with solid-dosage formulation directors and CDMO technical operations heads and excipient engineers and hospital pharmacy buyers across the value chain. Market sizing and segment estimates were validated against commercial tablet press capacity, prescription dispensing audits, and historical trend analysis without double counting bulk API trade.
